Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study.

ABSTRACT:

Introduction

Epigenetic modifications play an important role in progression and development of resistance in ^V600EBRAF positive metastatic melanoma. Therefore, we hypothesized that the action of vemurafenib (BRAF inhibitor) can be made more effective by combining with low dose decitabine (a DNA methyltransferase inhibitor). The primary objective of this phase lb study was to determine the dose limiting toxicity and maximum tolerated dose of combination of subcutaneous decitabine with oral vemurafenib in patients with ^V600EBRAF positive metastatic melanoma with or without any prior treatment.

Experimental design

The study employed 3+3 dose escalation combining subcutaneous decitabine at different doses and schedules (4 cohorts) with the standard oral dos

SUBMITTER: Zakharia Y 

PROVIDER: S-EPMC5687680 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature